Breaking News Instant updates and real-time market news.

ACRS

Aclaris Therapeutics

$13.41

-0.18 (-1.32%)

16:08
10/15/18
10/15
16:08
10/15/18
16:08

Aclaris to acquire worldwide rights to Rhofade from Allergan

Aclaris Therapeutics (ACRS) announced it has entered into a definitive asset purchase agreement with Allergan (AGN) Sales to acquire worldwide rights to RHOFADEcream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intellectual property for RHOFADE, which is approved for the topical treatment of persistent facial erythema associated with rosacea in adults. This transaction, which is subject to customary closing conditions, including certain governmental regulatory clearances, is expected to close in the fourth quarter of 2018. Allergan has agreed to provide support to Aclaris to allow for a smooth transition of RHOFADE. Under the terms of the agreement, the purchase price includes an upfront cash payment of $65M due at closing, a development milestone payment related to the potential development of an additional dermatology product, and tiered royalties on net sales. Allergan developed and brought RHOFADE to market in 2017 after acquiring the drug as part of its 2011 acquisition of Vicept Therapeutics, Inc., a company established by certain members of the current senior management team of Aclaris. "We are excited to acquire RHOFADE. Our team is very familiar with the asset and the market opportunity," said Dr. Neal Walker, President and Chief Executive Officer of Aclaris. "It is a rare opportunity to acquire an asset which was on a good trajectory with this level of initial launch activities completed." Expected synergies by leveraging current infrastructure and sales force in the U.S. RHOFADE is expected to be accretive to Aclaris' EBITDA beginning in the fourth quarter of 2019. Aclaris also today announced entering into a loan and security agreement with Oxford Finance LLC. Under the terms of the loan agreement, $30M will be made available for borrowing until October 31, 2018, and the remaining $35M will be made available upon the closing of the RHOFADE acquisition until March 31, 2019.

  • 27

    Nov

ACRS Aclaris Therapeutics
$13.41

-0.18 (-1.32%)

09/07/18
JEFF
09/07/18
NO CHANGE
Target $30
JEFF
Buy
Expectations for Aclaris Therapeutics' Eskata are low, says Jefferies
Jefferies analyst David Steinberg surveyed 50 physicians who treat a high volume of seborrheic keratosis patients to better understand their views on Aclaris Therapeutics' Eskata. Respondents indicated that 54% of their patients could potentially benefit from Eskata, Steinberg tells investors in a research note. Given that 83M Americans have some form of SK, the survey-derived peak sales estimate of $250M for Eskata "does not seem unreasonable," the analyst adds. He believe expectations for Eskata are low, "particularly considering the growing value" of Aclaris' late stage pipeline. Steinberg lowered his price target for the shares to $30 from $33 and keeps a Buy rating on Aclaris Therapeutics.
07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
04/10/18
CANT
04/10/18
NO CHANGE
Target $50
CANT
Overweight
Aclaris insider buying underscores attractive valuation, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen highlights "meaningful" recent insider buying from executive officers at Aclaris Therapeutics, including, CEO Neal Walker, CFO Frank Ruffo and Chairman Stephen Tullman. Chen believes the stock purchases underscore her view that Aclaris shares are undervalued. The market underappreciates the commercial opportunity for Eskata, A-101 for warts, JAK for hair loss as well as vitiligo and the Confluence assets, Chen tells investors in a research note. She keeps an Overweight rating on Aclaris Therapeutics with a $50 price target.
03/28/18
LEER
03/28/18
INITIATION
Target $52
LEER
Outperform
Aclaris Therapeutics assumed with an Outperform at Leerink
Leerink analyst Etzer Darout assumed coverage of Aclaris Therapeutics with an Outperform rating and $52 price target. The company's lead program Eskata offers a new treatment option for patients with seborrheic keratosis with reduced risk of dyspigmentation and scarring, the analyst tells investors in a research note.

TODAY'S FREE FLY STORIES

FB

Facebook

$189.02

0.21 (0.11%)

, TWTR

Twitter

$39.97

-0.29 (-0.72%)

12:37
10/16/19
10/16
12:37
10/16/19
12:37
On The Fly
#SocialStocks: Facebook still advancing Libra, Twitter clarifies rules »

Welcome to…

FB

Facebook

$189.02

0.21 (0.11%)

TWTR

Twitter

$39.97

-0.29 (-0.72%)

SNAP

Snap

$13.68

-0.41 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 30

    Oct

IRM

Iron Mountain

$32.64

-0.135 (-0.41%)

12:35
10/16/19
10/16
12:35
10/16/19
12:35
Options
Iron Mountain put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 12

    Nov

AMZN

Amazon.com

$1,776.00

7.3 (0.41%)

12:33
10/16/19
10/16
12:33
10/16/19
12:33
Hot Stocks
U.K.'s CMA announces formal investigation of Amazon's Deliveroo investment »

The Competition and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

NBEV

New Age Beverages

$2.73

(0.00%)

12:32
10/16/19
10/16
12:32
10/16/19
12:32
Hot Stocks
New Age Beverages says on Twitter that 'big news coming' for Nestea »

The official Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
10/16/19
10/16
12:30
10/16/19
12:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

NWL

Newell Brands

$19.31

0.14 (0.73%)

12:25
10/16/19
10/16
12:25
10/16/19
12:25
Options
Newell Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$37.04

0.77 (2.12%)

12:18
10/16/19
10/16
12:18
10/16/19
12:18
Hot Stocks
General Motors confirms UAW's statement regarding proposed tentative agreement »

GM said in a statement:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
10/16/19
10/16
12:17
10/16/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
10/16/19
10/16
12:16
10/16/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAN

Anaplan

$44.40

-3.33 (-6.98%)

12:15
10/16/19
10/16
12:15
10/16/19
12:15
Options
Anaplan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

MCK

McKesson

$146.86

8.69 (6.29%)

, ABC

AmerisourceBergen

$87.62

4.44 (5.34%)

12:11
10/16/19
10/16
12:11
10/16/19
12:11
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks continue in a…

MCK

McKesson

$146.86

8.69 (6.29%)

ABC

AmerisourceBergen

$87.62

4.44 (5.34%)

CAH

Cardinal Health

$49.76

1.83 (3.82%)

JNJ

Johnson & Johnson

$136.44

3.6 (2.71%)

TEVA

Teva

$7.33

0.37 (5.32%)

GM

General Motors

$37.14

0.87 (2.40%)

UAL

United Airlines

$90.00

2.1 (2.39%)

BA

Boeing

$376.35

5.36 (1.44%)

BAC

Bank of America

$30.38

0.64 (2.15%)

MGM

MGM Resorts

$27.47

-0.4 (-1.44%)

BX

Blackstone

$46.86

-0.24 (-0.51%)

ACHN

Achillion

$6.25

2.595 (71.00%)

ALXN

Alexion

$102.60

-2.245 (-2.14%)

SFIX

Stitch Fix

$22.00

1.17 (5.62%)

WDAY

Workday

$158.51

-22.33 (-12.35%)

SNBR

Sleep Number

$45.49

-1.2 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

WB

Weibo

$52.17

2.85 (5.78%)

12:05
10/16/19
10/16
12:05
10/16/19
12:05
Options
Weibo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.00

-0.41 (-7.58%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Aphria falls -8.1% »

Aphria is down -8.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NOW

ServiceNow

$251.40

-23.2 (-8.45%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
ServiceNow falls -8.3% »

ServiceNow is down -8.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Dec

AVD

American Vanguard

$13.39

-1.87 (-12.25%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
American Vanguard falls -12.6% »

American Vanguard is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

HOV

Hovnanian

$28.26

2.2 (8.44%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Hovnanian rises 8.2% »

Hovnanian is up 8.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.98

0.55 (8.55%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Owens & Minor rises 8.2% »

Owens & Minor is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$3.75

0.305 (8.85%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Fitbit rises 8.7% »

Fitbit is up 8.7%, or 30c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$37.17

0.9 (2.48%)

11:57
10/16/19
10/16
11:57
10/16/19
11:57
Hot Stocks
UAW sends proposed tentative deal to UAW GM members to ratify »

Following five weeks of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PDCO

Patterson Companies

$17.42

0.09 (0.52%)

, HSIC

Henry Schein

$62.68

0.83 (1.34%)

11:55
10/16/19
10/16
11:55
10/16/19
11:55
Hot Stocks
Judge rules Patterson Companies violated U.S. antitrust laws in FTC complaint »

Chief Administrative Law…

PDCO

Patterson Companies

$17.42

0.09 (0.52%)

HSIC

Henry Schein

$62.68

0.83 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 12

    Dec

HSIC

Henry Schein

$62.41

0.56 (0.91%)

11:50
10/16/19
10/16
11:50
10/16/19
11:50
Hot Stocks
Judge dismisses FTC complaint against Henry Schein »

Chief Administrative Law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 12

    Dec

XLF

Financial Select Sector

$28.06

-0.02 (-0.07%)

11:50
10/16/19
10/16
11:50
10/16/19
11:50
Options
Upside call buyer in Financial Sector ETF tied to hedge »

Upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRBT

iRobot

$58.37

0.58 (1.00%)

11:48
10/16/19
10/16
11:48
10/16/19
11:48
Hot Stocks
SharkNinja says 'will aggressively defend' against iRobot patent suit »

SharkNinja announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

RNET

RigNet

11:46
10/16/19
10/16
11:46
10/16/19
11:46
Initiation
RigNet initiated  »

RigNet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNI

ATN International

11:46
10/16/19
10/16
11:46
10/16/19
11:46
Initiation
ATN International initiated  »

ATN International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.